EAM
JBIO

Exome Asset Management’s Jade Biosciences JBIO Stock Holding History

Exome Asset Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,814
Closed -$2.91M – 55
2024
Q1 		$2.91M Buy
+2,814
New +$2.15M 2.49% 13

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Exome Asset Management's JBIO Position: Q2 2024 in Review

Exome Asset Management sold out of Jade Biosciences (JBIO) in Q2 2024, closing a stake of 2,814 shares — an estimated $2.91M sold.

Exome Asset Management first reported a position in JBIO in Q1 2024 and held it in 1 quarter. The position peaked at $2.91M in Q1 2024. 80 funds tracked by Wall St. Rank hold JBIO as of Q2 2024.

  • Exome Asset Management reported no remaining Jade Biosciences position as of Q2 2024 after selling out during the quarter.
  • Exome Asset Management sold 2,814 Jade Biosciences shares in Q2 2024, an estimated $2.91M.
  • Exome Asset Management first reported a position in Jade Biosciences in Q1 2024 and held it in 1 quarter.
  • Exome Asset Management's Jade Biosciences position peaked at $2.91M in Q1 2024.
  • 80 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2024.

Based on Exome Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.